Novo, s global life sciences investor, and Forbion, a venture capital firm, led a €26m investment round in Orbis Medicines, a macrocycle drug discovery company. “Oral macrocycles have the potential to disrupt large therapeutic areas historically dominated by IV and subcutaneous blockbuster antibodies and peptides with a convenient oral modality. We believe this evolution will expand the reach of important macrocycle-based medicines to a much larger group of patients. Orbis is addressing the limitations of first-generation macrocycle technologies based on its transformational, chemistry-led, machine learning-enabled platform which creates and assays hundreds of thousands of diverse compounds in record time to narrow in on the very best options. We are excited to welcome a highly respected investor, Forbion, to Orbis Medicines who shares our vision of building Orbis Medicines as a leading oral macrocycle company with an extensive pipeline across multiple therapeutic areas,” Morten Døssing, Orbis Chairperson and Novo Partner.